Royalty Pharma plc (RPRX) Profit Margin
Royalty Pharma plc (RPRX) net profit margin by fiscal period. Analyze profit margins in Excel with MarketXLS.
Profit Margin Data
| Period | Net Profit Margin |
|---|---|
| 2020-12-31 | 45.94% |
| 2021-12-31 | 27.07% |
| 2022-12-31 | 1.91% |
| 2023-12-31 | 48.20% |
| 2024-12-31 | 37.95% |
| 2025-12-31 | 32.42% |
How RPRX compares with sector peers
| Symbol | Company | Net profit margin (latest fiscal year) |
|---|---|---|
| EW | Edwards Lifesciences Corporation | 17.69% |
| NBIX | Neurocrine Biosciences Inc. | 16.73% |
| TMO | Thermo Fisher Scientific Inc | 15.05% |
| ABT | Abbott Laboratories | 14.72% |
| DHR | Danaher Corporation | 14.71% |
These are five companies in the same sector as RPRX with a comparable annual net profit margin. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Royalty Pharma plc Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Profit_Margin("RPRX", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | RPRX | $63.96 | +0.13% | 3.40M |
| 3 | ||||
| 4 | ||||
| 5 |